Arcturus Therapeutics Statistics
Share Statistics
Arcturus Therapeutics has 27.09M shares outstanding. The number of shares has increased by 0.64% in one year.
| Shares Outstanding | 27.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.17% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 24.58M |
| Failed to Deliver (FTD) Shares | 784 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 4.44M, so 16.4% of the outstanding shares have been sold short.
| Short Interest | 4.44M |
| Short % of Shares Out | 16.4% |
| Short % of Float | 18.07% |
| Short Ratio (days to cover) | 10 |
Valuation Ratios
The PE ratio is -28.24 and the forward PE ratio is -8.78.
| PE Ratio | -28.24 |
| Forward PE | -8.78 |
| PS Ratio | 5.32 |
| Forward PS | 1.3 |
| PB Ratio | 3.01 |
| P/FCF Ratio | -39.98 |
| PEG Ratio | n/a |
Enterprise Valuation
Arcturus Therapeutics Inc. has an Enterprise Value (EV) of 522.79M.
| EV / Earnings | -17.59 |
| EV / Sales | 3.31 |
| EV / EBITDA | -21.63 |
| EV / EBIT | -6.68 |
| EV / FCF | -24.89 |
Financial Position
The company has a current ratio of 4.72, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.72 |
| Quick Ratio | 4.72 |
| Debt / Equity | 0.11 |
| Total Debt / Capitalization | 9.79 |
| Cash Flow / Debt | -0.6 |
| Interest Coverage | -101.96 |
Financial Efficiency
Return on equity (ROE) is -0.11% and return on capital (ROIC) is -27%.
| Return on Equity (ROE) | -0.11% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -27% |
| Revenue Per Employee | 876.38K |
| Profits Per Employee | -165.14K |
| Employee Count | 180 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.83M |
| Effective Tax Rate | -0.07 |
Stock Price Statistics
The stock price has increased by -48.95% in the last 52 weeks. The beta is 2.64, so Arcturus Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.64 |
| 52-Week Price Change | -48.95% |
| 50-Day Moving Average | 17.62 |
| 200-Day Moving Average | 23.32 |
| Relative Strength Index (RSI) | 44.94 |
| Average Volume (20 Days) | 408.25K |
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 157.75M and earned -29.73M in profits. Earnings per share was -1.12.
| Revenue | 157.75M |
| Gross Profit | 154.79M |
| Operating Income | -78.20M |
| Net Income | -29.73M |
| EBITDA | -24.17M |
| EBIT | -78.20M |
| Earnings Per Share (EPS) | -1.12 |
Balance Sheet
The company has 292.00M in cash and 30.22M in debt, giving a net cash position of 261.79M.
| Cash & Cash Equivalents | 292.00M |
| Total Debt | 30.22M |
| Net Cash | 261.79M |
| Retained Earnings | -367.87M |
| Total Assets | 370.65M |
| Working Capital | 261.36M |
Cash Flow
In the last 12 months, operating cash flow was -18.10M and capital expenditures -2.90M, giving a free cash flow of -21.00M.
| Operating Cash Flow | -18.10M |
| Capital Expenditures | -2.90M |
| Free Cash Flow | -21.00M |
| FCF Per Share | -0.79 |
Margins
Gross margin is 98.13%, with operating and profit margins of -49.58% and -18.84%.
| Gross Margin | 98.13% |
| Operating Margin | -49.58% |
| Pretax Margin | -17.68% |
| Profit Margin | -18.84% |
| EBITDA Margin | -15.32% |
| EBIT Margin | -49.58% |
| FCF Margin | -13.31% |
Dividends & Yields
ARCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.8% |
| FCF Yield | -4.7% |
Analyst Forecast
The average price target for ARCT is $63, which is 282.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $63 |
| Price Target Difference | 282.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Nov 16, 2017. It was a backward split with a ratio of 1:7.
| Last Split Date | Nov 16, 2017 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | 1.95 |
| Piotroski F-Score | 2 |